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Delivery of genes via receptor-mediated endocytosis is severely limited by the poor exit of endocytosed DNA
from the endosome. A large enhancement in delivery efficiency has been obtained by including human
adenovirus particles in the delivery system. This enhancement is probably a function of the natural adenovirus
entry mechanism, which must include passage through or disruption of the endosomal membrane. In an effort
to identify safer virus particles useful in this application, we have tested the chicken adenovirus CELO virus
for its ability to augment receptor-mediated gene delivery. We report here that CELO virus possesses
pH-dependent, liposome disruption activity similar to that of human adenovirus type 5. Furthermore, the
chicken adenovirus can be used to augment receptor-mediated gene delivery to levels comparable to those
found for the human adenovirus when it is physically linked to polylysine ligand-condensed DNA particles. The
chicken adenovirus has the advantage of being produced inexpensively in embryonated eggs, and the virus is
naturally replication defective in mammalian cells, even in the presence of wild-type human adenovirus.
We have developed a receptor-mediated gene delivery
system (7, 8, 44, 47) which uses the endosomolytic activity
of adenovirus particles to enhance entry of DNA into target
cells (9, 12, 13, 43). Initial experiments were performed with
adenovirus dl312, a replication-defective, Ela-deficient
strain of human adenovirus type 5 (AdS) which can be grown
on the El-complementing cell line 293 (16, 19). The augmen-
tation phenomenon generated by the adenovirus particle
relies upon the use of high levels of adenovirus, in the range
of 3,000 to 10,000 virus particles per cell (60 to 200 PFU per
cell). Although we can observe greater than 90% transient
transfection efficiencies on a variety of cells types, treating
cells with this high multiplicity of dl312 particles can gener-
ate some toxicity problems. Some of these problems are
clearly due to the ability of d1312 to replicate in certain cell
types at high multiplicity of infection (19). Toxicity may also
result from the expression of various early or late viral genes
in the absence of viral replication. Psoralen-UV treatment of
adenovirus particles relieves much of the short-term toxicity
(9). However, we wondered whether genetic approaches
might complement chemical inactivation of virus particles.
Therefore, we are testing a variety of other viral particles for
their function in our system.
The ideal endosomolytic adenovirus particle would aug-
ment gene delivery as well as remain transcriptionally and
replicationally inert once it enters the target cell. One
approach might involve the use of adenovirus strains from
distant species. Members of the adenovirus family have been
isolated from birds, amphibians, and a variety of mammals
(18). An adenovirus from a distant species might show
reduced toxicity in the target cells, as chicken or frog
adenoviruses would not be expected to replicate or initiate
substantial gene expression in mammalian cells. Viruses
from distant species would present a reduced hazard to the
investigator and would be less subject to interference by
antibodies against human or murine adenovirus when these
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viruses are used in gene therapy experiments in mice and
humans. We have chosen to test the chicken adenovirus
CELO (chicken embryo lethal orphan) virus, (46) in our
DNA delivery system. CELO virus shows no reactivity to
antibodies that recognize the major group epitopes of the
adenoviruses infecting mammalian cells.
A limit to the use of the chicken virus in mammalian cells
may be the entry of the virus into the cell if a receptor for this
virus is not present on mammalian cells. This problem can be
solved by coupling the chicken virus to DNA-polylysine
(pLys) complexes containing a ligand for mammalian cells
(e.g., transferrin), a strategy that has been successfully used
to carry Ad5-DNA complexes into human blood cells (43).
To test these ideas, CELO virus (avian adenovirus type 1)
was tested for its ability to augment DNA delivery into
mammalian cells in a fashion analogous to the use of human
AdS. In many cell types, the chicken virus works with
efficiencies comparable to those of the human adenovirus.
We find, however, that coupling the virus to the cargo DNA
is essential for high-efficiency transport, consistent with the
idea that the chicken virus alone is not efficiently internal-
ized by these cells. The chicken virus appears to be less
toxic than the human AdS mutant dl312. This lack of toxicity
facilitates the isolation of stable expressing clones at effi-
ciencies of 5 to 10%.
MATERUILS AND METHODS
CELO virus (Phelps strain, serotype FAV-1; kindly sup-
plied by Gerhard Monreal and Sabine Schuller, Institut fur
Geflugelkrankheiten, Freie Universitat Berlin) was used in
these experiments. The initial strain (adapted for cell culture
growth) was serially passaged five times in 9-day chicken
embryos to enhance viral yields. Approximately 1010 virus
particles in 100 ,ul of N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES)-buffered saline (HBS; 150 mM
NaCl, 20 mM HEPES [pH 7.4]) were injected into the
allantoic cavity of 8- to 10-day chicken embryos. After a 90-h
incubation at 37°C in a humidified incubator, the allantoic
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fluid was harvested (approximately 8 ml per egg) and clari-
fied by low-speed centrifugation (1,000 x g, 10 min). The
clarified supernatant (25 ml) was then layered on top of 10 ml
of 1.45-g/ml CsCl (in 20 mM HEPES [pH 7.4]) and centri-
fuged for 1 h at 25,000 rpm. The virus-free supernatant was
removed and replaced with a fresh aliquot of the clarified
allantoic fluid, and the centrifugation was repeated. This
process was repeated two to three times per CsCl pad. The
virus, which accumulates as an opalescent band just below
the egg supernatant-CsCl interface, was collected, the sam-
ple was adjusted to a density of 1.34 g/ml with CsCl, and the
material was centrifuged to equilibrium in a Beckman Vti-65
centrifuge rotor (63,000 rpm, >4 h). CELO virus bands at an
apparent density of 1.35 g/ml. At least two and often three
CsCl equilibrium centrifugations were required to generate
virus of sufficient purity. The final purified virus was used
directly for biotinylation.
For biotinylation, the virus (2 ml in ca. 1.35-g/ml CsCl-20
mM HEPES [pH 7.4], i.e., virus directly from a CsCl
gradient) was reacted with 20 ,ul of 1 mM NHS-LC-Biotin
(Pierce catalog no. 21335, freshly dissolved in 10 mM
HEPES [pH 7.9]) for 3 h at room temperature. The biotin-
ylated virus was then dialyzed four times against 300 ml of
HBS-40% glycerol at 4°C and subsequently stored in ali-
quots at -70°C. Virus quantitation was performed by mea-
suring virus protein and using the conversion factor 1 mg of
virus protein = 3.4 x 1012 virus particles (25) developed for
human adenovirus type 5 studies. The Ela-defective adeno-
virus d1312 (19) grown in 293 cells (16) was purified and
biotinylated as previously described (9, 43).
All DNA samples used were purified by double CsCl
purification as described previously (8). Plasmid pCLuc is
described in reference 30; plasmid pWeLuc and cosmid
CosLuc are described in reference 9; pCMV,3gal is described
in reference 29. The synthesis of human transferrin-pLys
(TfpL) was performed as described in reference 41. Strepta-
vidin-pLys (StrpL) conjugate preparation is described in
reference 43. Assays for luciferase were performed as de-
scribed in reference 8. Briefly, cells to be harvested were
washed once with phosphate-buffered saline (PBS) and
scraped into a minimum volume of PBS by using a plastic
policeman. The cells were then collected by centrifugation,
the cell pellet was washed once with PBS, and finally the
cells were suspended in 100 pl of 200 mM Tris (pH 7.5) per
5 x 105 cells. The cells were then disrupted by three
freeze-thaw cycles and centrifuged at 15,000 x g for 5 min,
and the supernatants, standardized for protein content, were
assayed for luciferase activity (8). All experiments were
repeated two to three times with similar relative luciferase
values within each experiment, although absolute values of
luciferase varied between experiments. Staining of cells with
5-bromo-4-chloro-3-indolyl-4-D-galactopyranoside (X-Gal)
for P-galactosidase activity was carried out as described in
reference 28.
RESULTS
Adenovirus d1312 and CELO virus display pH-dependent
membrane disruption activity. A variety of experiments
support the notion that adenovirus enhances receptor-medi-
ated gene delivery by disrupting the endosome in a pH-
dependent manner. Human adenovirus has been found to
disrupt liposomes in a pH-dependent fashion (5); several of
the viral capsid proteins increase their hydrophobicity (as
measured by detergent binding) as the pH is lowered below
5 (36), and adenovirus permeabilizes cell membranes at pH 6
(34, 35). We tested the membrane disruption activity of
adenoviruses by using a liposome leakage assay in which a
lipid membrane encapsidates a high, self-quenching concen-
tration of the fluorescent dye calcein (42). When lesions are
generated in the lipid bilayer, the resulting leakage and
dilution of the dye result in an increase in the fluorescence of
the sample. Therefore, measurement of the fluorescence
increase yields an indication of the membrane disruptive
activity of a sample. Furthermore, strong correlations be-
tween pH-dependent liposome disruption and effective DNA
delivery have been found for endosomolytic peptide-pLys
conjugates (42). We wanted to compare the pH-dependent
liposome disruption activity of CELO virus with that of the
human Ad5, which we know augments receptor-mediated
gene delivery to a high level (9, 12, 13, 43).
Samples of Ad5 (d1312) and CELO virus were tested for
liposome disruption activity as a function of pH. We find that
both viruses display time-dependent liposomolytic activity
in this assay at pH 5.0, with no liposome leakage generated
at pH 7 (Fig. 1A). Human Ad5 maintains approximately 50%
of its pH 5 activity at pH 5.5 and 6.0, dropping to near-
background levels at pH 7, while CELO virus displays a
much sharper increase in liposome disruption going from pH
5.5 to 5.0 (Fig. 1B). This finding is slightly different from the
liposome disruption data obtained by Blumenthal et al. (5)
for Ad2, which showed a very apparent optimum at pH 6.0.
CELO virus, while displaying 24% greater activity than did
the human virus at pH 5.0, has less than half of the Ad5
activity at higher pHs.
CELO virus augments DNA delivery in HeLa and C2C12
cells. The TfpL-condensed gene and adenovirus particles
were added to cells expressing both the transferrin receptor
and the adenovirus receptor. Binding and coendocytosis of
both materials can occur. The low pH of the endosome is
thought to allow the adenovirus particle to trigger a mem-
brane disruption (endosomolysis) which allows both the
virus and coendocytosed DNA to enter the cytoplasm.
Successful gene delivery in this system is measured by the
resulting luciferase activity.
We supplied HeLa cells with TfpL-DNA (pCLuc) com-
plexes alone, in the presence of free adenovirus d1312, or in
the presence of an equal quantity of CELO virus (Fig. 2A,
lines 1 to 3). These are conditions similar to those used for
the original free adenovirus augmentation of DNA delivery
(12). We observe the expected 350-fold augmentation of
DNA delivery by d1312 (line 2) as measured by the resulting
luciferase activity. However, the optimum quantity of
CELO virus, while triggering a modest increase in DNA
delivery (approximately 16-fold; compare lines 1 and 3), was
20-fold less active than the human adenovirus d1312. We
suspected that one cause of the poor activity might be
inefficient binding and internalization of the chicken virus by
human cells.
Previously we found that coupling human adenovirus
d1312 to TfpL-DNA complexes is crucial for efficient deliv-
ery into blood cells (43), which are deficient in binding and/or
internalization of adenovirus (17, 38). We concluded that
presenting the virus in this context allows efficient internal-
ization via the transferrin receptor. We wondered whether a
similar ploy might be used to carry the chicken adenovirus
into human cells. Therefore, we prepared biotinylated
CELO virus and used a StrpL bridge to attach the virus to
TfpL-DNA complexes. These new complexes can enter
human cells via the transferrin receptor or via pLys-cell
interactions, carrying with them the endosomolytic activity
of CELO virus.
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FIG. 1. pH-dependent membrane disruption activities of adeno-
virus d1312 and CELO virus. (A) CsCl-purified adenovirus or CELO
virus (3 p.g of protein) was incubated with 1 ml of 200 mM NaCl-20
mM sodium citrate (pH 7.0 or 5.0) containing iso-osmolar, calcein-
loaded liposomes (42). The fluorescence increase (excitation at 495
nm, measurement at 515 nm) at the indicated times was measured
and expressed as a percentage of the 100% fluorescence value
(obtained by adding 5 p.l of 10% Triton X-100 to the sample at the
end of the incubation period) after subtracting the background
leakage values. Background leakage values were obtained from
liposome samples exposed to identical volumes of the virus storage
buffer (HBS-40% glycerol) incubated over the same time and pH
values. (B) Adenovirus or CELO virus samples were analyzed as in
panel A with 1 ml of 200 mM NaCl-20 mM sodium citrate (pH 7.0,
6.5, 6.0, 5.5, or 5.0) containing calcein-loaded liposomes. The
fluorescence increase at 30 min was measured and expressed as a
percentage of the 100% fluorescence value.
The delivery by human adenovirus is improved only
threefold by coupling the DNA to the virus (Fig. 2A, line 5
versus line 2), probably because there are sufficiently high
levels of human adenovirus and transferrin receptors on
these cells to allow coendocytosis of uncoupled virus and
TfpL-DNA complexes. When CELO virus is supplied to
HeLa cells coupled directly to the TfpL-DNA, we find that
the resulting DNA delivery (Fig. 2A, line 6) is greatly
increased, so that its activity is comparable to the activity
obtained with either the coupled (line 5) or free (line 2) d1312.
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FIG. 2. Augmentation of DNA delivery in HeLa cells by CELO
virus. HeLa cells (A) or C2C12 myoblasts (B; 5 x 105 cells per
6-cm-diameter dish) were incubated in 2 ml of Dulbecco modified
Eagle medium supplemented with 2% heat-inactivated fetal calf
serum with 6 p.g of plasmid pCLuc (30) complexed with the
indicated pLys or TfpL mixtures in 500 ,ul of HBS incubated for 30
min at room temperature. The samples were then added to the cells
at 37°C in the presence of 18 ,ul of d1312 (1012 virus particles per ml;
sample 2) or 30 p,l of CELO virus (1011 virus particles per ml; sample
3). With the samples containing biotinylated virus coupled to
StrpL-DNA, the same quantities of either biotinylated d1312 (sample
5) or biotinylated CELO virus (sample 6) were preincubated with 1
p.g of StrpL in 200 pl. of HBS for 30 min at room temperature before
addition of 6 ,ug of plasmid pCLuc in 100 p,l of HBS. After a 30-min
room temperature incubation, 7 ,ug of TfpL (containing 3.5 p,g of
pLys) in 100 p,l of HBS was added. After a final 30-min room
temperature incubation, the material was added to cells at 37°C.
Two hours later, 5 ml of Dulbecco's modified Eagle medium
supplemented with 10% fetal calf serum was added to all cells; 24 h
later, the cells were harvested and processed for the luciferase
assay.
Therefore, providing a new internalization route for CELO
virus allows it to function with activity comparable to that of
the human adenovirus. Note, however, that even in the
absence of the StrpL bridge, the CELO virus delivery
activity is not zero (Fig. 2, line 1 versus line 3). The major
capsid protein of the chicken adenovirus, hexon, is quite
acidic, containing nearly 26 mol% aspartic and glutamic acid
residues (24); as a consequence, intact virus particles can
bind to pLys-agarose and are eluted by high salt concentra-
tions (unpublished data). Thus, a stable interaction between
pLys in the TfpL-DNA complex and the acidic CELO virus
capsid might explain the partial DNA delivery activity seen
in the absence of specific CELO virus-DNA complex cou-
pling.
We next tested CELO virus in the C2C12 myoblast cell
line. These cells have been used as a model system for
myoblast gene delivery because of their ability to differenti-
ate into long-lasting myotubes (3, 14). We have observed
that adenovirus-augmented DNA delivery functions well in
-
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FIG. 3. Improvement of CELO virus DNA delivery in C2C12
myoblasts by using WGA as a ligand. C2C12 myoblasts were
transfected with 6 jig of pCMVL complexed with 1 jig of StrpL and
7 ,ug of TfpL alone (sample 1) or plus 5 ,ul of biotinylated adenovirus
d1312 (10' particles per ml; sample 2) or 18 ,ul of biotinylated CELO
virus (0.3 x 1012 particles per ml; sample 3). These complexes were
prepared as described for Fig. 2. Samples 4 to 7, containing 6 ,ug of
pCLuc plus StrpL, biotinylated CELO virus, and biotinylated WGA
(WGA-B; 2 to 4 mol of biotin per mol of protein; Boehringer
Mannheim), were prepared in the following manner. Virus (18 ,ul,
0.3 x 1012 particles per ml) and WGA were mixed in 150 ,ul of HBS.
StrpL was diluted in 150 p.l of HBS, and the two solutions were
mixed and incubated at room temperature for 30 min. The DNA
sample (in 100 p.l of HBS) was added to the StrpL-virus-WGA
solution and then incubated for another 30 min at room temperature.
Finally, 3.5 p.g of pLys 300 in 100 p.l of HBS was added to the
mixture, and again the sample was incubated at room temperature
for 30 min. The complexes were supplied to C2C12 myoblasts (5 x
105 cells per 6-cm-diameter dish) in 2 ml of Dulbecco's modified
Eagle medium plus 2% fetal calf serum. One hour later, 5 ml of
Dulbecco modified Eagle medium plus 10% fetal calf serum was
added to the cells; 20 h later, the cells were processed for luciferase
activity measurement. The activity (light units) in each entire cell
sample is displayed.
these cells but only if the adenovirus is coupled directly to
the DNA complex. In contrast to the results for HeLa cells,
CELO virus is 100-fold less active than d1312 in myoblasts,
even in the TfpL-StrpL-coupled configuration (Fig. 2B, lines
2 and 3). One explanation might be that both the transferrin
ligand and the CELO virus ligand are poorly internalized by
these cells. We therefore sought a new ligand for the C2C12
cells.
CELO virus DNA delivery in C2C12 myoblasts is improved
by using WGA as a ligand. The lectin wheat germ agglutinin
(WGA), which binds N-acetylglucosamine residues, is a
ligand for muscle cells (15, 22). We wondered whether the
inclusion of WGA in our CELO virus-DNA complexes might
improve binding and subsequent internalization of DNA
supplied to C2C12 cells. Therefore, we prepared either the
previously tested StrpL-TfpL-CELO DNA complexes or
StrpL-CELO DNA complexes containing increasing
amounts of biotinylated WGA and presented these com-
plexes to C2C12 cells. The TfpL-CELO complexes resulted
in the low delivery previously observed (ca. 2 x 106 light
units; Fig. 3, line 3), compared with 9 x 107 light units
obtained with dl312-TfpL complexes (line 2). Merely replac-
ing the TfpL with unmodified pLys generated a large in-
crease in delivery (line 4), probably because pLys bound an
as yet unidentified cell surface protein on C2C12 cells (37).
Inclusion of the lectin WGA (in a biotinylated form) in the
complexes generated a further twofold increase in delivery
(lines 5 and 6). This configuration of CELO virus now allows
DNA delivery to C2C12 cells with efficiencies comparable to
that obtained with the human adenovirus (Fig. 3; compare
lines 2 and 6). Further increases in WGA content produce
complexes that are less efficient, probably because of com-
petition between biotinylated components and StrpL (line 7).
A major improvement in CELO virus activity comes from
coupling the virus to pLys-DNA complexes, whereas includ-
ing transferrin in the CELO virus complex results in much
lower activity. This apparent inhibitory activity of the trans-
ferrin ligand on CELO virus activity with C2C12 cells could
be a function of the pH encountered by the virus during
internalization. The CELO virus endosomolytic activity
displays a sharp increase going from pH 5.5 to 5, whereas the
adenovirus d1312 profile shows much greater activity at the
intermediate range (pH 6.0 to 5.5; Fig. 1). Perhaps the DNA
delivery activity of CELO virus requires a low lysosomal pH
(<6.0) that is not obtained with the transferrin-transferrin
receptor pair (which cycles down to only pH 6.0 before
returning to the surface [6]). Other possible explanations
include limited transferrin receptor numbers or recycling on
C2C12 cells or transferrin shielding of the PLys binding
effect.
CELO virus augments DNA delivery to levels comparable to
those obtained with adenovirus d1312 but displays much less
cellular toxicity. One major difficulty with the use of adeno-
virus d1312 may be the leakiness of the replication defect.
Some of the activities of the deleted gene in d1312, Ela, can
be compensated by a number of other viral and cellular
proteins, including the E7 protein of human papillomavirus
expressed in HeLa cells (26). One indication of this phenom-
enon is the appearance of HeLa cell cultures 48 to 72 h after
a >90% efficient, d1312-augmented transfection. The cells
are beginning to detach and round up, with the typical
features of adenovirus-induced cytopathic effect (Fig. 4C
and D, d1312 versus CELO at 72 h posttransfection). The
extent of this cytopathic effect varies from low in primary,
nontransformed cultures to extreme in cultures of primary
human tumor cells (e.g., melanoma cells; unpublished data).
Therefore, to test the toxicity of CELO virus, we performed
a DNA transfection into HeLa cells and compared transfec-
tion efficiencies and cytopathic effects 72 to 96 h posttrans-
fection.
HeLa cells were transfected with expression plasmids
(luciferase or LacZ) and either biotinylated d1312 in a TfpL-
StrpL complex or biotinylated CELO in a StrpL-pLys
complex, using optimum virus quantities of 10,000 (d1312) or
3,000 (CELO) virus particles per cell. In parallel, HeLa cells
were exposed to a serial dilution series of the optimum
virus-DNA complexes. After 72 h, cells were harvested for
the luciferase assay (Fig. 4B), stained with crystal violet to
determine the number of surviving cells (Fig. 4A), or ex-
posed to X-Gal to reveal the 1-galactosidase activity (Fig.
4C).
We find that the two viruses deliver comparable quantities
of gene expression as measured by luciferase activity (Fig.
4B) and 0-galactosidase activity (Fig. 4C). However, the
10,000 d1312 virus particles per cell caused cytopathic effects
resulting in a loss of approximately 30 to 50% of the cells
(Fig. 4A and C). Threefold-higher levels of d1312 result in
complete loss of the cell culture. In contrast, the CELO
virus transfection is well tolerated by HeLa cells. Although
3-fold lower quantities of CELO virus relative to d1312 can
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FIG. 4. Evidence that CELO virus augments DNA delivery to levels comparable to those obtained with adenovirus d1312 but displays little
cellular toxicity. (A) HeLa cells were plated in a 24-well dish (5 x 104 cells per well) and 24 h later placed in Dulbecco's modified Eagle
medium plus 2% fetal calf serum. Aliquots (660 ,ul) of biotinylated CELO virus (3.9 x 109 virus particles)-l ,ug of StrpL-3.5 jig of pLys-6
jig of pCLuc, biotinylated adenovirus d1312 (3.2 x 10i virus particles)-7 jig of TfpL-1 jg of StrpL-6 jig of pCLuc, or 3-fold serial dilutions
(in HBS) of these complexes were then added to each well. After a 2-h incubation at 37°C, the medium was removed and replaced with 2 ml
of Dulbecco's modified Eagle medium plus 10% fetal calf serum. After 72 h, the medium was removed, and the cell layer was fixed for 5 min
with 4% formaldehyde-150 mM NaCl and then stained for 10 min with 0.1% crystal violet in 2% ethanol. The staining solution was then
removed, and the well was washed twice with PBS. The bound crystal violet was solubilized in 500 jil of 96% ethanol, and the well was
washed with an additional 100 jil of 96% ethanol, which was added to the first wash. The crystal violet was quantitated by measuring theA595.
(B) Virus-DNA complexes as described for panel A were supplied to 5 x 105 HeLa cells in 6-cm-diameter dishes containing 1 ml of Dulbecco
modified Eagle medium plus 2% fetal calf serum. After 2 h, the medium was replaced with 5 ml of Dulbecco's modified Eagle medium plus
10% fetal calf serum; 72 h later, the cells were harvested and assayed for luciferase activity. (C and D) Virus-DNA complexes as described
for panel A (containing 6 jig of pCMVAgal [29]) were supplied to 5 x 1i5 HeLa cells in 6-cm-diameter dishes containing 1 ml of Dulbecco
modified Eagle medium plus 2% fetal calf serum. After 2 h, the medium was replaced with 5 ml of Dulbecco's modified Eagle medium plus
10% fetal calf serum; 72 h later, the cells were fixed and stained for ,3-galactosidase activity. (C) Cells transfected with adenovirus d1312
complexes; (D) cells transfected with CELO virus complexes.
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be used to generate similar expression levels, exposure of
these cells to even 10-fold-higher levels of virus produces no
apparent cell death (Fig. 4A).
Myoblast differentiation after exposure to adenovirus or
CELO virus. Adenovirus infection can interfere with myo-
blast differentiation (23), with the major interference attrib-
uted to Ela expression (45). Although adenovirus d1312 (Ela
minus) was reported to have little effect on the expression of
the myotube-specific marker myosin heavy chain (23), we
have consistently observed an altered morphology and tim-
ing of differentiation in myoblasts transfected with com-
plexes containing d1312 and induced to differentiate (data not
shown). Therefore, we transfected C2C12 myoblasts with a
P-galactosidase gene in complexes containing either adeno-
virus d1312 or CELO virus. We then induced the myoblasts
to differentiate by exposure to 2% horse serum and fixed and
stained the resulting cells 5 days later to examine both their
morphology and the level of gene expression (Fig. 5).
We find similar levels of P-galactosidase activity for the
two viruses. However, compared with the d1312 sample, the
resulting myotubes are much larger in the CELO virus-
treated sample and approach the sizes obtained with non-
transfected, differentiated cultures. The ability of CELO
virus-transfected myoblasts to form apparently normal my-
otube structures will have important consequences as we
attempt to integrate transfected myoblasts into existing
muscle structures in vivo.
Long-term, stable expression of genes delivered with the aid
of CELO virus. Although the efficiency of transient gene
expression obtained with the human adenovirus is greater
than 90% in many cell types, we have had great difficulty
selecting stable expressing cell clones after treatment with
the levels of adenovirus d1312 required for this high-level
expression (unpublished results). The limited toxicity of
CELO virus (Fig. 4 and 5) led us to attempt long-term gene
expression studies with CELO virus.
We introduced plasmids containing a neomycin phos-
photransferase (neo) gene into HeLa or C2C12 cells by using
TfpL alone or in complexes with adenovirus d1312 or as
pLys complexes with CELO virus. The virus and DNA
complex conditions used were those optimized for each
virus for transient (24- to 48-h) luciferase expression. At 48 h
posttransfection, cells were trypsinized and placed at vari-
ous dilutions in medium containing G418 at 200 ,g/ml
(HeLa) or 400 ,ug/ml (C2C12). After 14 days selection, the
resulting neomycin-resistant colonies (with greater than 300
cells) were quantitated by crystal violet staining.
With HeLa cells, no stable clones were obtained with the
adenovirus complexes. This finding is consistent with the
appearance of the cells after 72 h; nearly all cells had
detached and were rounded, with the appearance of virus
replication. No clones were obtained when cells were
treated with TfpL complexes alone, consistent with the low
level of transient gene expression obtained with this treat-
ment (Fig. 1 to 4). However, the CELO virus transfections
produced neomycin-resistant colonies at a rate of up to ca.
16% (i.e., 16 colonies per 100 transfected cells plated; Fig.
6).
Similar experiments were performed with C2C12 cells. In
addition, the efficiencies of stable delivery of small plasmids
(5 or 12 kb) versus a cosmid (48 kb) containing the same neo
gene were compared. The C2C12 cells transfected with
CELO virus complexes containing small plasmids gave rise
to stable expressing clones at efficiencies of 2 to 13% (Fig. 6).
Of considerable interest is the ability to generate clones with
the 48-kb cosmid with no reduced frequencies relative to the
smaller DNA molecules. Both the 12- and 48-kb molecules
contain identical RSV/LTR luciferase genes (9). When single
colonies from both the 12-kb transfection and the 48-kb
transfection were isolated, expanded, and tested for lu-
ciferase activity, comparable levels of expression were ob-
tained (data not shown). Note that the cloning efficiency of
C2C12 cells in the absence of neomycin selection is approx-
imately 40%. Therefore, the efficiencies of 2 to 13% might
actually represent true efficiencies of 5 to 30%.
DISCUSSION
We have demonstrated that the chicken adenovirus CELO
virus displays an endosomolytic activity similar to that of
human adenoviruses. This endosomolytic activity is inde-
pendent of receptor binding and can be demonstrated di-
rectly by measuring pH-dependent liposome disruption (Fig.
1). CELO virus can be used to augment receptor-mediated
gene delivery analogously to use of the human adenoviruses,
with several advantages. Mammalian cells treated with the
chicken virus do not show the long-term (48- to 72-h)
cytopathic effects often displayed by cells treated with high
levels of adenovirus d1312. This lack of cytotoxicity facili-
tates gene expression experiments not allowed by the human
adenovirus. One difference between the two types of viruses
is their capacity to bind and be internalized by mammalian
cells. The subgroup C adenovirus receptor is fairly wide-
spread on mammalian cell types, with a lowered binding
observed only with blood cells (17, 38). Our use of CELO
virus to augment receptor-mediated gene transfer has re-
quired techniques that introduce new cell-binding ligands on
the virus-DNA complex. In the end, however, the lack of
endogenous mammalian cell binding capacity on CELO
virus may facilitate specific cell targeting applications, using,
for example, cell-specific ligands such as a tetragalactose
ligand for liver-specific targeting (30) or cell-specific antibod-
ies. Because of the broad distribution of the type C adeno-
virus receptor, this type of cell targeting is not possible with
use of complexes that contain human AdS strains.
We are aware that CELO virus, although replication
incompetent in mammalian cells (20, 27, 33), is capable of
generating tumors in newborn hamsters after long incubation
times (1, 20, 33). We are monitoring this transforming
capacity carefully and have thus far seen no evidence of
human or mouse cell transformation in our experiments.
However, the baby hamster tumor production capacity of
CELO virus is completely blocked by exposing the virus
briefly to UV light (20). Therefore, one solution may involve
extending the psoralen-UV inactivation strategy that has
functioned with human adenovirus particles (9) to CELO
virus. Another approach may involve the generation of
transformation-defective mutants or the use of chicken ade-
noviruses that are not implicated in disease (10, 11).
The currently used El-defective recombinant adenovi-
ruses being considered for gene therapy applications (2, 4,
21, 31, 32, 39, 40; see reference 4 for a review) are certainly
replication defective in cell culture in the appropriate cell
types. However, in a mixed population of recombinant
adenovirus and wild-type adenovirus, the defective recom-
binant is complemented by the wild type. Depending on the
new gene carried by the recombinant virus, this may pose a
problem for use of these viruses in human patients, in whom
the absence of wild-type adenovirus cannot be ensured. In
contrast, the chicken adenovirus is completely replication
defective in human cells even in the presence of wild-type
J. VIROL.
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FIG. 5. Myoblast differentiation after exposure to CELO or d1dl312. Samples of 5 x 105 C2C12 myoblasts (in 6-cm-diameter dishes) were
transfected with pCMV,Bgal DNA in complexes containing either CELO virus plus WGA or d1312 as described for Fig. 3B. At 24 h
posttransfection, the medium was changed to 2% horse serum containing Dulbecco's modified Eagle medium to induce myoblast fusion and
differentiation. After 5 days, the cells were fixed and stained for ,B-galactosidase activity. (A and C) Cells transfected with adenovirus d1312
complexes; (B and D) cells transfected with CELO virus complexes.
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FIG. 6. G418-stable colony formation. Cells were transfected
with the optimum conditions for HeLa cells (Fig. 2A, sample 6) or
for C2C12 cells (Fig. 3, samples 4 or 6), using 6 ,ug of DNA per S x
105 cells. At 48 h after transfection, the cells were trypsinized and
aliquots were replated in selection medium containing G418 at 200
,ug/ml (HeLa) or 400 ±g/ml (C2C12). The dishes were stained with
crystal violet at 14 days after initiation of selection, and colonies
containing more than 300 cells were scored. The values reported are
the frequency of colony appearance per 100 cells plated and repre-
sent the averages of four independent transfections. The 12- and
48-kb DNA samples used were pWeLuc (12 kb) and CosLuc (48 kb),
described previously (9). These DNA molecules contain the neo
gene under the control of a simian virus 40 promoter. The 5-kb
plasmid used is a 5-kb AatI fragment used to generate the 12-kb
pWeLuc (9), containing the same simian virus 40 neo gene.
human adenovirus sequences (27). This may be a useful
safety feature of CELO virus.
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